First-in-human Study Evaluating the Safety, Tolerability and Immunogenicity of i.n. Administration of a Personalized Vaccination With IVAC MUTANOME Vaccine w/o Initial Treatment With RBL001/RBL002 Vaccine in Patients With Advanced Melanoma
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Aug 2019
Price : $35 *
At a glance
- Drugs BNT 121 (Primary) ; RBL 001/RBL 002 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; First in man
- Sponsors BioNTech; Ribological
- 02 Aug 2019 Planned End Date changed from 1 Mar 2019 to 1 Oct 2019.
- 13 Nov 2018 Planned End Date changed from 1 Apr 2018 to 1 Mar 2019.
- 09 Jan 2018 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History